Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adoption of a New Haemophilus influenzae Type b Vaccine Recommendation

Adoption of a New Haemophilus influenzae Type b Vaccine Recommendation Abstract Sir.—Haemophilus influenzae type b (Hib) infection in children is responsible for approximately 12 000 cases of meningitis and 7500 cases of other invasive diseases annually in the United States,1,2 with a mortality rate of 5% in cases of meningitis and as many as 40% of survivors having significant neurologic sequelae.3 On October 4, 1990, the Food and Drug Administration (FDA) permitted one Hib vaccine manufacturer to amend its package insert to claim safety and efficacy for administration at age 2 months.4 The previous recommended age of first administration had been 15 months. The American Academy of Pediatrics (AAP) soon issued a recommendation for first administration to infants at age 2 months. A letter called a Ped-Comm was sent from the AAP to its members in late October 1990 recommending the earlier age for first vaccination, but information on safety or efficacy was not included since References 1. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment . JAMA . 1985:253:521-529.Crossref 2. Broome CV. Epidemiology of Haemophilus influenzae, type b infections in the United States . Pediatr Infect Dis J. 1987;6:779-782.Crossref 3. Feigin RD. Bacterial meningitis beyond the neonatal period . In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Disease . Philadelphia, Pa: WB Saunders Co; 1987:439-477. 4. HHS News . Washington, DC: US Dept of Health and Human Services; (October 4) ,1990:1-3. 5. Centers for Disease Control. Recommendations and Reports . MMWR . 1991;40( (RR) -1):1-7. 6. DiFrancesco E. Manufacturer requests lower age for Hib immunization . Infect Dis Child. 1990;3:10-11. 7. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? N Engl J Med. 1989; 321:1306-1311.Crossref 8. Wilde JA, Pedroni AT. Your liability for vaccine-related injuries . Contemp Pediatr. 1991; 8:51-54. 9. Bauer RA, Wortzel LH. Doctor's choice: the physician and his sources of information about drugs . J Marketing Res. 1966;3:40-47.Crossref 10. Menzel H, Katz E. Social relations and innovation in the medical profession: the epidemiology of a new drug . Public Opinion Q. Winter 1956;19:337-352.Crossref 11. Coleman J, Menzel H, Katz E. Social processes in physicians' adoption of a new drug . J Chronic Dis. 1959;9:1-19.Crossref 12. Williamson PM. The adoption of new drugs by doctors practicing in group and solo practice . Soc Sci Med. 1975;9:233-236.Crossref 13. Becker MH, Stoley PD, Lasagna L. Differential education concerning therapeutics and resultant physician prescribing patterns . J Med Educ. 1972;47:118-127. 14. Coser RL. Authority and decision making in a hospital: a comparative analysis . Am Sociol Rev. 1958;23:56-64.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Adoption of a New Haemophilus influenzae Type b Vaccine Recommendation

Loading next page...
 
/lp/american-medical-association/adoption-of-a-new-haemophilus-influenzae-type-b-vaccine-recommendation-NA0kBZ0E4x

References (16)

Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1993.02160260014004
Publisher site
See Article on Publisher Site

Abstract

Abstract Sir.—Haemophilus influenzae type b (Hib) infection in children is responsible for approximately 12 000 cases of meningitis and 7500 cases of other invasive diseases annually in the United States,1,2 with a mortality rate of 5% in cases of meningitis and as many as 40% of survivors having significant neurologic sequelae.3 On October 4, 1990, the Food and Drug Administration (FDA) permitted one Hib vaccine manufacturer to amend its package insert to claim safety and efficacy for administration at age 2 months.4 The previous recommended age of first administration had been 15 months. The American Academy of Pediatrics (AAP) soon issued a recommendation for first administration to infants at age 2 months. A letter called a Ped-Comm was sent from the AAP to its members in late October 1990 recommending the earlier age for first vaccination, but information on safety or efficacy was not included since References 1. Cochi SL, Broome CV, Hightower AW. Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment . JAMA . 1985:253:521-529.Crossref 2. Broome CV. Epidemiology of Haemophilus influenzae, type b infections in the United States . Pediatr Infect Dis J. 1987;6:779-782.Crossref 3. Feigin RD. Bacterial meningitis beyond the neonatal period . In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Disease . Philadelphia, Pa: WB Saunders Co; 1987:439-477. 4. HHS News . Washington, DC: US Dept of Health and Human Services; (October 4) ,1990:1-3. 5. Centers for Disease Control. Recommendations and Reports . MMWR . 1991;40( (RR) -1):1-7. 6. DiFrancesco E. Manufacturer requests lower age for Hib immunization . Infect Dis Child. 1990;3:10-11. 7. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? N Engl J Med. 1989; 321:1306-1311.Crossref 8. Wilde JA, Pedroni AT. Your liability for vaccine-related injuries . Contemp Pediatr. 1991; 8:51-54. 9. Bauer RA, Wortzel LH. Doctor's choice: the physician and his sources of information about drugs . J Marketing Res. 1966;3:40-47.Crossref 10. Menzel H, Katz E. Social relations and innovation in the medical profession: the epidemiology of a new drug . Public Opinion Q. Winter 1956;19:337-352.Crossref 11. Coleman J, Menzel H, Katz E. Social processes in physicians' adoption of a new drug . J Chronic Dis. 1959;9:1-19.Crossref 12. Williamson PM. The adoption of new drugs by doctors practicing in group and solo practice . Soc Sci Med. 1975;9:233-236.Crossref 13. Becker MH, Stoley PD, Lasagna L. Differential education concerning therapeutics and resultant physician prescribing patterns . J Med Educ. 1972;47:118-127. 14. Coser RL. Authority and decision making in a hospital: a comparative analysis . Am Sociol Rev. 1958;23:56-64.Crossref

Journal

American Journal of Diseases of ChildrenAmerican Medical Association

Published: Feb 1, 1993

There are no references for this article.